France Cell & Gene Therapy Cold Chain Logistics Market to Grow with a CAGR of 14.22% through 2028

According to TechSci Research report, “France Cell & Gene Therapy Cold Chain Logistics Market – By Region, Competition, Forecast and Opportunities, 2028”, the France Cell & Gene Therapy Cold Chain Logistics Market stood at USD 83.63 million in 2022 and is anticipated to grow with a CAGR of 14.22% in the forecast period, 2024-2028. This can be attributed to the emergence of advanced therapies. Biotechnology has fueled the emergence of advanced therapies, such as CRISPR-based gene editing and CAR-T cell therapies. These therapies hold immense promise for treating previously incurable diseases. However, their delicate nature requires stringent temperature controls throughout the supply chain. The evolution of these advanced therapies is intricately linked to the parallel development of cold chain logistics solutions capable of preserving their potency and viability.

Furthermore, the digitalization of documentation and compliance processes is streamlining regulatory adherence in the logistics sector. Electronic data management systems, blockchain technology, and digital platforms for documentation are becoming increasingly prevalent. These advancements not only improve efficiency but also contribute to enhanced traceability and transparency throughout the supply chain.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "France Cell & Gene Therapy Cold Chain Logistics Market”

The cell and gene therapy sector in France has witnessed a growing demand for efficient cold chain logistics solutions. These logistics play a crucial role in maintaining the integrity and viability of sensitive biological materials throughout the supply chain, ensuring the safe and effective delivery of cell and gene therapies.

The market for cell and gene therapy cold chain logistics in France has experienced notable growth, driven by advancements in biotechnology and an increasing number of clinical trials and commercialization of these innovative therapies.

The France Cell & Gene Therapy Cold Chain Logistics Market is segmented into component, services offered, mode of transportation, holding temperature range, end user, regional distribution, and company.

Based on its component, Cryogenic shippers are poised to dominate the Cell & Gene Therapy Cold Chain Logistics Market in France for several compelling reasons. The intricate and sensitive nature of cell and gene therapies demands a highly precise and stable temperature-controlled environment, and cryogenic shippers excel in providing and maintaining ultra-low temperatures essential for preserving the integrity of these advanced therapies. Their ability to maintain consistent temperature levels during transportation ensures the viability and efficacy of the biological materials involved in these therapies. Additionally, the increasing adoption of cell and gene therapies in France necessitates a reliable and efficient cold chain logistics system, where cryogenic shippers play a pivotal role. The advanced technology and stringent temperature control features of cryogenic shippers align perfectly with the stringent regulatory requirements and quality standards governing the transportation of cell and gene therapy products. As the demand for these innovative therapies continues to rise, the dominance of cryogenic shippers in the French market is poised to grow, ensuring the seamless and secure delivery of these life-changing treatments.

Based on end user, Pharmaceutical and biotechnology companies are positioned to emerge as dominant end-users in the Cell & Gene Therapy Cold Chain Logistics Market in France due to their pivotal role in driving advancements and innovation in the field. The intricate nature of cell and gene therapies requires substantial expertise, infrastructure, and investment, elements that pharmaceutical and biotechnology companies possess in abundance. These entities are at the forefront of developing cutting-edge therapies and are instrumental in bringing them from the research stage to commercialization. Given their extensive involvement in the production and distribution of cell and gene therapies, pharmaceutical and biotechnology companies have a vested interest in establishing robust cold chain logistics systems. Their commitment to ensuring the integrity, safety, and efficacy of these therapies positions them as key stakeholders in shaping the logistics landscape. As the demand for personalized and advanced therapies continues to escalate, the dominance of pharmaceutical and biotechnology companies as end-users in the French market is set to grow, reflecting their central role in driving the success and accessibility of cell and gene therapies.

 Major companies operating in France Cell & Gene Therapy Cold Chain Logistics Market are:

• World Courier Lyon
• United Parcel Service France SAS
• Catalent, Inc.
• BioLife Solutions, Inc.
• Cryoport, Inc.
• Thermo Fisher Scientific (FEI France SAS)

Download Free Sample Report

Customers can also request for 10% free customization on this report

“The future of France's Cell & Gene Therapy Cold Chain Logistics Market is marked by innovation, collaboration, and a commitment to meeting the unique challenges posed by these groundbreaking therapies. As the industry embraces advanced technologies, sustainable practices, and adapts to evolving regulatory landscapes, the logistics infrastructure supporting cell and gene therapies is poised to become more resilient and efficient. Navigating the upcoming trends will be essential for ensuring the continued success of cell and gene therapy logistics in France's dynamic biopharmaceutical ecosystem,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

“France Cell & Gene Therapy Cold Chain Logistics Market By Component (Cryogenic Shippers, Cryogenic Storage Freezers, Ultra Low Freezers, Cold Chain Management Systems, Shipment and Storage Medium, Cryogenic Packout Kits, Others {Shipment Containers, Reusable Boxes, etc.}), By Services Offered (Transportation, Storage, Packaging), By Mode of Transportation (Air, Ground, Water), By Holding Temperature Range (Cryogenic, Refrigerated, Ambient, Others {Deep Freezers, Dry Ice, etc.}), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others), By Region, By Competition Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of France Cell & Gene Therapy Cold Chain Logistics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in France Cell & Gene Therapy Cold Chain Logistics Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]

Website: www.techsciresearch.com